These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 26506405)

  • 21. Exploring the size limit of templates for inhibitors of the M2 ion channel of influenza A virus.
    Duque MD; Ma C; Torres E; Wang J; Naesens L; Juárez-Jiménez J; Camps P; Luque FJ; DeGrado WF; Lamb RA; Pinto LH; Vázquez S
    J Med Chem; 2011 Apr; 54(8):2646-57. PubMed ID: 21466220
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Viral M2 ion channel protein: a promising target for anti-influenza drug discovery.
    Moorthy NS; Poongavanam V; Pratheepa V
    Mini Rev Med Chem; 2014; 14(10):819-30. PubMed ID: 25342196
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Structure-activity relationships of 3-O-β-chacotriosyl oleanic acid derivatives as entry inhibitors for highly pathogenic H5N1 influenza virus.
    Li S; Jia X; Shen X; Wei Z; Jiang Z; Liao Y; Guo Y; Zheng X; Zhong G; Song G
    Bioorg Med Chem; 2017 Aug; 25(16):4384-4396. PubMed ID: 28651913
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Design, synthesis and structure-activity relationship of novel inhibitors against H5N1 hemagglutinin-mediated membrane fusion.
    Zhu Z; Li R; Xiao G; Chen Z; Yang J; Zhu Q; Liu S
    Eur J Med Chem; 2012 Nov; 57():211-6. PubMed ID: 23059548
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Virtual Screening Identifies Chebulagic Acid as an Inhibitor of the M2(S31N) Viral Ion Channel and Influenza A Virus.
    Duncan MC; Onguéné PA; Kihara I; Nebangwa DN; Naidu ME; Williams DE; Balgi AD; Andrae-Marobela K; Roberge M; Andersen RJ; Niikura M; Ntie-Kang F; Tietjen I
    Molecules; 2020 Jun; 25(12):. PubMed ID: 32599753
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Design and synthesis of pinane oxime derivatives as novel anti-influenza agents.
    Dong J; Xiao M; Ma Q; Zhang G; Zhao W; Kong M; Zhang Y; Qiu L; Hu W
    Bioorg Chem; 2020 Sep; 102():104106. PubMed ID: 32739481
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Slow but Steady Wins the Race: Dissimilarities among New Dual Inhibitors of the Wild-Type and the V27A Mutant M2 Channels of Influenza A Virus.
    Barniol-Xicota M; Gazzarrini S; Torres E; Hu Y; Wang J; Naesens L; Moroni A; Vázquez S
    J Med Chem; 2017 May; 60(9):3727-3738. PubMed ID: 28418242
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Amantadine-oseltamivir combination therapy for H5N1 influenza virus infection in mice.
    Ilyushina NA; Hoffmann E; Salomon R; Webster RG; Govorkova EA
    Antivir Ther; 2007; 12(3):363-70. PubMed ID: 17591026
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Steered molecular dynamics approach for promising drugs for influenza A virus targeting M2 channel proteins.
    Nguyen H; Le L
    Eur Biophys J; 2015 Sep; 44(6):447-55. PubMed ID: 26033540
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Discovery of Highly Potent Inhibitors Targeting the Predominant Drug-Resistant S31N Mutant of the Influenza A Virus M2 Proton Channel.
    Li F; Ma C; DeGrado WF; Wang J
    J Med Chem; 2016 Feb; 59(3):1207-16. PubMed ID: 26771709
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Expeditious Lead Optimization of Isoxazole-Containing Influenza A Virus M2-S31N Inhibitors Using the Suzuki-Miyaura Cross-Coupling Reaction.
    Li F; Hu Y; Wang Y; Ma C; Wang J
    J Med Chem; 2017 Feb; 60(4):1580-1590. PubMed ID: 28182419
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Combination chemotherapy, a potential strategy for reducing the emergence of drug-resistant influenza A variants.
    Ilyushina NA; Bovin NV; Webster RG; Govorkova EA
    Antiviral Res; 2006 Jul; 70(3):121-31. PubMed ID: 16516984
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Discovery of highly potent agents against influenza A virus.
    Zhao X; Li C; Zeng S; Hu W
    Eur J Med Chem; 2011 Jan; 46(1):52-7. PubMed ID: 21094565
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Arylazolyl(azinyl)thioacetanilide. Part 9: Synthesis and biological investigation of thiazolylthioacetamides derivatives as a novel class of potential antiviral agents.
    Zhan P; Wang L; Liu H; Chen X; Li X; Jiang X; Zhang Q; Liu X; Pannecouque C; Naesens L; De Clercq E; Liu A; Du G
    Arch Pharm Res; 2012 Jun; 35(6):975-86. PubMed ID: 22870806
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A Study of the Activity of Adamantyl Amines against Mutant Influenza A M2 Channels Identified a Polycyclic Cage Amine Triple Blocker, Explored by Molecular Dynamics Simulations and Solid-State NMR.
    Stampolaki Μ; Hoffmann A; Tekwani K; Georgiou K; Tzitzoglaki C; Ma C; Becker S; Schmerer P; Döring K; Stylianakis I; Turcu AL; Wang J; Vázquez S; Andreas LB; Schmidtke M; Kolocouris A
    ChemMedChem; 2023 Aug; 18(16):e202300182. PubMed ID: 37377066
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Structural and energetic analysis of drug inhibition of the influenza A M2 proton channel.
    Gu RX; Liu LA; Wei DQ
    Trends Pharmacol Sci; 2013 Oct; 34(10):571-80. PubMed ID: 24011996
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Symmetric dimeric adamantanes for exploring the structure of two viroporins: influenza virus M2 and hepatitis C virus p7.
    Mandour YM; Breitinger U; Ma C; Wang J; Boeckler FM; Breitinger HG; Zlotos DP
    Drug Des Devel Ther; 2018; 12():1019-1031. PubMed ID: 29750015
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Flipping in the pore: discovery of dual inhibitors that bind in different orientations to the wild-type versus the amantadine-resistant S31N mutant of the influenza A virus M2 proton channel.
    Wu Y; Canturk B; Jo H; Ma C; Gianti E; Klein ML; Pinto LH; Lamb RA; Fiorin G; Wang J; DeGrado WF
    J Am Chem Soc; 2014 Dec; 136(52):17987-95. PubMed ID: 25470189
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Design, synthesis, and in vitro biological evaluation of 1H-1,2,3-triazole-4-carboxamide derivatives as new anti-influenza A agents targeting virus nucleoprotein.
    Cheng H; Wan J; Lin MI; Liu Y; Lu X; Liu J; Xu Y; Chen J; Tu Z; Cheng YS; Ding K
    J Med Chem; 2012 Mar; 55(5):2144-53. PubMed ID: 22332894
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Why amantadine loses its function in influenza m2 mutants: MD simulations.
    Laohpongspaisan C; Rungrotmongkol T; Intharathep P; Malaisree M; Decha P; Aruksakunwong O; Sompornpisut P; Hannongbua S
    J Chem Inf Model; 2009 Apr; 49(4):847-52. PubMed ID: 19281265
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.